ALPHARETTA, Ga., March 16, 2016 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the Company’s attendance schedule for upcoming 2016 Spring and Summer medical device shows and medical conferences.
- Korea International Medical and Hospital Equipment Show (KIMES 2016) - The 32nd annual Korea International Medical and Hospital Equipment Show (KIMES 2016) will be held at COEX, Seoul, South Korea from March 17 – 20, 2016. SANUWAVE’s exclusive South Korean distributor, Mr. Byung Ho Lee of KOVE will be exhibiting the Company’s orthoPACE® device for orthopedic and musculoskeletal conditions. Mr. Kevin A. Richardson II, Chairman of the Board and CEO of SANUWAVE will also be in attendance. This show will be the first to introduce newly approved indications for treating Diabetic Foot Ulcers (DFU) and the first and only such indication for devices treating DFU in South Korea. Visit with Mr. Richardson and Mr. Lee at booth D245.
- Symposium on Advance Wound Care (SAWC Spring 2016) - The Symposium on Advanced Wound Care Spring and Wound Healing Society (SAWC Spring/WHS) meeting being held in Atlanta, GA from April 13 – 17, 2016, is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, researchers, and scientists are expected to attend the 2016 SAWC Spring/WHS meeting in Atlanta.
- Wound, Ostomy and Continence Nurses Society (WOCN) The Wound, Ostomy and Continence Nurses Society Conference (WOCN) will be held in Montreal, Canada, June 4 – 8, 2016. WOCN is recognized world-wide for the promotion of safe and effective wound, ostomy and continence (WOC) care. Leading health care organizations recognize the WOCN Society as the premiere nursing specialty organization to educate clinicians to improve WOC patient outcomes.
- APMA 2016 – The National 2016, this year’s event for the American Podiatric Medical Association Annual Conference will be held in Philadelphia, PA from July 14 – 17, 2016. The National is the podiatric medical profession's premier foot and ankle conference.
Company management will be available for one-on-one meetings with investors participating in the conferences. For those who would like to schedule an appointment with SANUWAVE’s management, please contact Kevin Richardson II at 978-922-2447 or via email at firstname.lastname@example.org.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Source:SANUWAVE Health, Inc.